Trial intelligence / Profile preview

Avutometinib and Defactinib in MPNST

NCT07743554Phase 2Not yet recruiting

Start: Jan 2027
Primary completion: Jan 2031

Overview

Phase 2, open-label, single-arm trial of avutometinib and defactinib in malignant peripheral nerve sheath tumor (MPNST). Primary endpoint: Progression-Free Survival at 4 months. Planned start Jan 2027; status: not yet recruiting.

Drugs

avutometinibdefactinib

Conditions

malignant peripheral nerve sheath tumor (MPNST)

Beyond the preview

Go deeper on NCT07743554.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT07743554.